ICU MEDICAL INC/DE

ICU Medical's stockholders approved significant amendments to the company's Amended and Restated Certificate of Incorporation, eliminating supermajority voting requirements and allowing stockholders owning at least 25% of voting power to call special meetings. These changes, along with corresponding Bylaw amendments, became effective on May 15, 2026. Additionally, at the Annual Meeting, stockholders elected seven directors, ratified Deloitte & Touche LLP as the independent auditor, and approved executive compensation on an advisory basis.

ICU Medical reported a net income of $30.1 million, or $1.22 per diluted share, for the first quarter of 2026, a significant improvement from a net loss of $15.5 million, or $(0.63) per diluted share, in the prior year. Total revenues decreased by 12.3% to $530.2 million, primarily due to the divestment of a 60% ownership interest in its IV Solutions business in May 2025. The company also noted an immaterial divestiture of certain assets in March 2026.

ICU Medical announced its first quarter 2026 financial results, reporting a GAAP revenue decline of 12% to $530.2 million, primarily due to the divestiture of its IV Solutions business. However, non-GAAP organic revenue, excluding the divestiture and foreign currency impacts, increased by 1%. The company achieved a GAAP net income of $30.1 million, a significant improvement from a net loss in the prior year, and adjusted diluted EPS grew to $1.97.

ICU Medical, Inc. announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, at approximately 4:00 p.m. ET. The company will host a conference call to discuss these results at 4:30 p.m. ET on the same day. Investors can access the call via a toll-free number or a live webcast on the company's investor relations website.